Document is current
Any future updates will be listed below
-
Authors
Mills, Joseph
Tessari, Anna
Anastas, Vollter
Sunilkumar, Damu
Samadi Rad, Nastaran
Lamba, Saranya
Cosentini, Ilaria
Reers, Ashley
Zhu, Zirui
Miles, Wayne O.
Coppola, Vincenzo
Cocucci, Emanuele
Magliery, Thomas J.
Shive, Heather
Davies, Alexander E.
Rizzotto, Lara
Croce, Carlo M.
Palmieri, Dario
-
Funding
Funding for this research was provided by:
The Ohio State University President's Research Excellence Award
Office of Research Infrastructure Programs (K01OD031811-01)
NIH-NCI (P30CA016058)
- License Information
-
More Information
Article History
Received: 9 November 2024
Accepted: 24 April 2025
First Online: 14 July 2025
Declarations
:
: Not applicable.
: Not applicable.
: DP and CMC are inventors of the patent application WO2017011411 A1 (methods and compositions relating to anti-NCL recombinant immunoagents). DP and TJM are consultants and own equity of Koru Biopharma, which is developing anti-NCL agents.
